Joyce A. Goldstein

Joyce A. Goldstein's AcademicInfluence.com Rankings

Joyce A. Goldstein

Medical

#3099

World Rank

#3554

Historical Rank

Pharmacology

#368

World Rank

#419

Historical Rank

medical Degrees

Download Badge

Medical

Joyce A. Goldstein's Degrees

PhD Pharmacology University of California, San Francisco
Bachelors Biochemistry University of California, Berkeley

Why Is Joyce A. Goldstein Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Joyce A. Goldstein's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. (1994) (961)
Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. (1994) (795)
Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. (2002) (696)
Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. (2001) (656)
The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. (1996) (641)
Biochemistry and molecular biology of the human CYP2C subfamily. (1994) (517)
Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. (2001) (493)
Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans. (1994) (368)
Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. (1997) (357)
Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. (2001) (353)
Kidney function influences warfarin responsiveness and hemorrhagic complications. (2009) (271)
Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. (2001) (247)
Metabolism of chlorpyrifos by human cytochrome P450 isoforms and human, mouse, and rat liver microsomes. (2001) (241)
Separation of pure polychlorinated biphenyl isomers into two types of inducers on the basis of induction of cytochrome P-450 or P-448. (1977) (232)
A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. (1998) (226)
Induction of Human CYP2C9 by Rifampicin, Hyperforin, and Phenobarbital Is Mediated by the Pregnane X Receptor (2004) (223)
Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs (1999) (216)
Human CYP2C8 Is Transcriptionally Regulated by the Nuclear Receptors Constitutive Androstane Receptor, Pregnane X Receptor, Glucocorticoid Receptor, and Hepatic Nuclear Factor 4α (2005) (190)
Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. (1997) (187)
Identification of constitutive androstane receptor and glucocorticoid receptor binding sites in the CYP2C19 promoter. (2003) (186)
Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele. (1999) (179)
Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes. (1998) (174)
Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups. (2003) (170)
Amodiaquine Metabolism is Impaired by Common Polymorphisms in CYP2C8: Implications for Malaria Treatment in Africa (2007) (165)
Expression of CYP1A1 and CYP1A2 genes in human liver. (1993) (164)
The hydroxylation of omeprazole correlates with S‐mephenytoin metabolism: A population study (1995) (162)
Regulation of human CYP2C9 by the constitutive androstane receptor: discovery of a new distal binding site. (2002) (159)
Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P450 2C19. (2001) (158)
Detection of Human CYP2C8, CYP2C9, and CYP2J2 in Cardiovascular Tissues (2007) (157)
Ovarian hormones enhance 2,3,7,8-tetrachlorodibenzo-p-dioxin-mediated increases in cell proliferation and preneoplastic foci in a two-stage model for rat hepatocarcinogenesis. (1991) (155)
Identification of the human P450 enzymes involved in lansoprazole metabolism. (1996) (155)
Mechanism of action and structure-activity relationships for the chlorinated dibenzo- p- dioxins and related compounds (1989) (152)
Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans. (2008) (152)
Dose-response relationships for chronic exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin in a rat tumor promotion model: quantification and immunolocalization of CYP1A1 and CYP1A2 in the liver. (1992) (150)
Discovery of new potentially defective alleles of human CYP2C9. (2004) (146)
Correlation of human cytochrome P4502C substrate specificities with primary structure: warfarin as a probe. (1993) (144)
Genetic analysis of the S‐mephenytoin polymorphism in a chinese population (1995) (142)
Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin. (1998) (138)
Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation. (1997) (137)
Identification and functional characterization of new potentially defective alleles of human CYP2C19. (2002) (137)
The transcriptional regulation of the human CYP2C genes. (2009) (131)
A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin. (1999) (126)
Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism. (1996) (124)
Differential induction of two 2,3,7,8-tetrachlorodibenzo-p-dioxin-inducible forms of cytochrome P-450 in extrahepatic versus hepatic tissues. (1984) (122)
Midazolam Metabolism in Cytochrome P450 3A Knockout Mice Can Be Attributed to Up-Regulated CYP2C Enzymes (2008) (119)
Cloning and expression of murine CYP2Cs and their ability to metabolize arachidonic acid. (1998) (118)
The Nuclear Receptors Constitutive Androstane Receptor and Pregnane X Receptor Cross-Talk with Hepatic Nuclear Factor 4α to Synergistically Activate the Human CYP2C9 Promoter (2005) (116)
An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians. (1998) (114)
VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans. (2008) (110)
Single nucleotide polymorphisms in the CYP2J2 and CYP2C8 genes and the risk of hypertension (2005) (109)
THE STRUCTURE‐ACTIVITY RELATIONSHIPS OF HALOGENATED BIPHENYLS AS ENZYME INDUCERS (1979) (103)
A multifamily study on the relationship between CYP2C19 genotype and s-mephenytoin oxidation phenotype. (1995) (101)
Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes. (1996) (95)
Tolbutamide, Flurbiprofen, and Losartan as Probes of CYP2C9 Activity in Humans (2003) (95)
Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. (1991) (95)
Effects of pentachlorophenol on hepatic drug-metabolizing enzymes and porphyria related to contamination with chlorinated dibenzo-p-dioxins and dibenzofurans. (1977) (94)
Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests. (2005) (93)
CYP2C44, a New Murine CYP2C That Metabolizes Arachidonic Acid to Unique Stereospecific Products (2004) (93)
Interaction of hexachlorobenzene with the receptor for 2,3,7,8-tetrachlorodibenzo-p-dioxin in vitro and in vivo. Evidence that hexachlorobenzene is a weak Ah receptor agonist. (1989) (88)
Experimental hepatic porphyria induced by polychlorinated biphenyls. (1974) (83)
Functional Characterization of Novel Allelic Variants of CYP2C9 Recently Discovered in Southeast Asians (2005) (81)
Advances in mechanisms of activation and deactivation of environmental chemicals. (1993) (79)
Cloning, expression, and characterization of three new mouse cytochrome p450 enzymes and partial characterization of their fatty acid oxidation activities. (2004) (78)
In vitro human metabolism and interactions of repellent N,N-diethyl-m-toluamide. (2002) (75)
Human CYP2C8 Is Post-Transcriptionally Regulated by MicroRNAs 103 and 107 in Human Liver (2012) (75)
Transcriptional regulation of human CYP2C genes: functional comparison of CYP2C9 and CYP2C18 promoter regions. (1995) (75)
Toxicological assessment of hexachlorobiphenyl isomers and 2,3,7,8,-tetrachlorodibenzofuran in chicks. II. Effects on drug metabolism and porphyrin accumulation. (1976) (75)
Identification of Residues 99, 220, and 221 of Human Cytochrome P450 2C19 as Key Determinants of Omeprazole Hydroxylase Activity (*) (1996) (74)
Recombinant CYP3A4*17 Is Defective in Metabolizing the Hypertensive Drug Nifedipine, and the CYP3A4*17 Allele May Occur on the Same Chromosome as CYP3A5*3, Representing a New Putative Defective CYP3A Haplotype (2005) (74)
Hepatic porphyria induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin in the mouse. (1973) (72)
The effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) on the hepatic estrogen and glucocorticoid receptors in congenic strains of Ah responsive and Ah nonresponsive C57BL/6J mice. (1991) (72)
Histone H3K4 trimethylation by MLL3 as part of ASCOM complex is critical for NR activation of bile acid transporter genes and is downregulated in cholestasis. (2011) (71)
Oxidation of uroporphyrinogen by methylcholanthrene-induced cytochrome P-450. Essential role of cytochrome P-450d. (1989) (71)
Differences in flurbiprofen pharmacokinetics between CYP2C9*1/*1, *1/*2, and *1/*3 genotypes (2003) (70)
Enhanced biliary excretion of thyroxine glucuronide in rats pretreated with benzpyrene. (1968) (69)
2,3,7,8-Tetrachlorodibenzofuran in a commercially available 99% pure polychlorinated biphenyl isomer identified as the inducer of hepatic cytochrome P-448 and aryl hydrocarbon hydroxylase in the rat. (1978) (69)
Effects of a polybrominated biphenyl mixture in the rat and mouse. I. Six-month exposure. (1983) (67)
Mouse Liver CYP2C39 Is a Novel Retinoic Acid 4-Hydroxylase (2004) (67)
Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy. (2009) (66)
Purification and characterization of a second form of hepatic cytochrome P-448 from rats treated with a pure polychlorinated biphenyl isomer. (1982) (66)
Increases in cytochrome P-450 mediated 17 beta-estradiol 2-hydroxylase activity in rat liver microsomes after both acute administration and subchronic administration of 2,3,7,8-tetrachlorodibenzo-p-dioxin in a two-stage hepatocarcinogenesis model. (1988) (65)
Validation of precision-cut liver slices in dynamic organ culture as an in vitro model for studying CYP1A1 and CYP1A2 induction. (1996) (65)
Gene structure and upstream regulatory regions of human CYP2C9 and CYP2C18. (1993) (64)
Identification and localization of five CYP2Cs in murine extrahepatic tissues and their metabolism of arachidonic acid to regio- and stereoselective products. (2001) (63)
Isolation of a new canine cytochrome P450 CDNA from the cytochrome P450 2C subfamily (CYP2C41) and evidence for polymorphic differences in its expression. (1998) (62)
A comparative study of two polychlorinated biphenyl mixtures (Aroclors 1242 and 1016) containing 42% chlorine on induction of hepatic porphyria and drug metabolizing enzymes. (1975) (58)
Torsemide metabolism by CYP2C9 variants and other human CYP2C subfamily enzymes. (2000) (58)
Evaluation of cytochrome P4502C9 metabolic activity with tolbutamide in CYP2C9*1 heterozygotes (2002) (58)
Med25 Is Required for RNA Polymerase II Recruitment to Specific Promoters, Thus Regulating Xenobiotic and Lipid Metabolism in Human Liver (2010) (58)
Identification of residues 286 and 289 as critical for conferring substrate specificity of human CYP2C9 for diclofenac and ibuprofen. (1998) (57)
Disposition of 2,3,7,8-tetrabromodibenzo-p-dioxin and 2,3,7,8-tetrachlorodibenzo-p-dioxin in the rat: biliary excretion and induction of cytochromes CYP1A1 and CYP1A2. (1991) (57)
Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450 2C subfamily (1991) (56)
Influence of the Ah locus on the effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on the hepatic epidermal growth factor receptor. (1991) (56)
Hormonal regulation of male-specific rat hepatic cytochrome P-450g (P-450IIC13) by androgens and the pituitary. (1989) (55)
Suppression of the constitutive, male-specific rat hepatic cytochrome P-450 2c and its mRNA by 3,4,5,3',4',5'-hexachlorobiphenyl and 3-methylcholanthrene. (1987) (53)
Genetic polymorphism of S-mephenytoin 4'-hydroxylation in African-Americans. (1996) (53)
Assessment of the contribution of chlorinated dibenzo-p-dioxins and dibenzofurans to hexachlorobenzene-induced toxicity, porphyria, changes in mixed function oxygenases, and histopathological changes. (1978) (52)
The constitutive active/androstane receptor regulates phenytoin induction of Cyp2c29. (2004) (52)
P2X7 receptor-NADPH oxidase axis mediates protein radical formation and Kupffer cell activation in carbon tetrachloride-mediated steatohepatitis in obese mice. (2012) (51)
Effects of purified and technical piperonyl butoxide on drug-metabolizing enzymes and ultrastructure of rat liver. (1973) (50)
Immunochemical evidence for two 3-methylcholanthrene-inducible forms of cytochrome P-448 in rat liver microsomes using a double-antibody radioimmunoassay procedure. (1983) (49)
The chronic toxicity of technical and analytical pentachlorophenol in cattle. I. Clinicopathology. (1980) (48)
Phenytoin Induction of the Cyp2c37 Gene Is Mediated by the Constitutive Androstane Receptor (2006) (47)
Cyclophosphamide and 4-hydroxycyclophosphamide pharmacokinetics in patients with glomerulonephritis secondary to lupus and small vessel vasculitis. (2012) (46)
Human CYP2C-mediated stereoselective phenytoin hydroxylation in Japanese: difference in chiral preference of CYP2C9 and CYP2C19. (1999) (46)
Specificity of rat liver cytochrome P-450 isozymes in the mutagenic activation of benzo[a]pyrene, aromatic amines and aflatoxin B1. (1983) (46)
Induction of porphyria in the rat by chronic versus acute exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin. (1982) (45)
Hepatocyte Nuclear Factor 4α Regulates Rifampicin-Mediated Induction of CYP2C Genes in Primary Cultures of Human Hepatocytes (2010) (44)
Analysis of the CYP2C19 polymorphism in a North-eastern Thai population. (2002) (44)
The role of the Ah locus in hexachlorobenzene-induced porphyria. Studies in congenic C57BL/6J mice. (1988) (44)
Phenotypic differences in expression of cytochrome P-450g but not its mRNA in outbred male Sprague-Dawley rats. (1987) (43)
Liganded pregnane X receptor represses the human sulfotransferase SULT1E1 promoter through disrupting its chromatin structure (2011) (42)
Identification of human CYP2C19 residues that confer S-mephenytoin 4'-hydroxylation activity to CYP2C9. (2001) (41)
Evaluation of potential losartan‐phenytoin drug interactions in healthy volunteers * (2002) (40)
Induction of cytochrome P-450 isozymes by hexachlorobenzene in rats and aromatic hydrocarbon (Ah)-responsive mice. (1986) (39)
Nuclear Receptor Coactivator 6 Mediates the Synergistic Activation of Human Cytochrome P-450 2C9 by the Constitutive Androstane Receptor and Hepatic Nuclear Factor-4α (2008) (39)
Losartan and E3174 Pharmacokinetics in Cytochrome P450 2C9*1/*1, *1/*2, and *1/*3 Individuals (2003) (39)
Cytochrome P4501A1 mediates the metabolism of 2,3,7,8-tetrachlorodibenzofuran in the rat and human. (1993) (38)
Cloning of canine cytochrome P450 2E1 cDNA: identification and characterization of two variant alleles. (2000) (37)
Enzyme-Mediated Protein Haptenation of Dapsone and Sulfamethoxazole in Human Keratinocytes: I. Expression and Role of Cytochromes P450 (2006) (35)
CYP2C19 genotyping and associated mephenytoin hydroxylation polymorphism in a Canadian Inuit population. (1996) (35)
CYP2C40, a unique arachidonic acid 16-hydroxylase, is the major CYP2C in murine intestinal tract. (2000) (34)
Genetic Polymorphisms in Human Drug Metabolic Enzymes (1997) (31)
Structure-activity relationships of chlorinated benzenes as inducers of different forms of cytochrome P-450 in rat liver. (1982) (31)
Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. [Erratum to document cited in CA114(15):137136r] (1993) (31)
Pharmacogenetics in clinical pharmacology and toxicology. (1995) (30)
RBCK1, an E3 Ubiquitin Ligase, Interacts with and Ubiquinates the Human Pregnane X Receptor (2013) (30)
A single amino acid mutation (Ser180----Cys) determines the polymorphism in cytochrome P450g (P4502C13) by altering protein stability. (1992) (29)
CYP2C9 genotype and pharmacodynamic responses to losartan in patients with primary and secondary kidney diseases (2009) (29)
A comparison of a commercial polybrominated biphenyl mixture, 2,4,5,2',4',5'-hexabromobiphenyl and 2,3,6,7-tetrabromonaphthalene as inducers of liver microsomal drug-metabolizing enzymes. (1979) (28)
Associations of ABCB1 3435C>T and IL-10-1082G>A Polymorphisms With Long-Term Sirolimus Dose Requirements in Renal Transplant Patients (2011) (28)
Covalent binding to DNA and mutagenicity of 2,4-diaminotoluene metabolites produced by isolated hepatocytes and 9000 g supernatant from Fischer 344 rats. (1987) (28)
Identification of Human CYP2C8 as a Retinoid-Related Orphan Nuclear Receptor Target Gene (2009) (27)
Differences in the Incidence of the CYP 2 C 19 Polymorphism Affecting the S-Mephenytoin Phenotype in Chinese Han and Bai Populations and Identification of a New Rare CYP 2 C 19 Mutant Allele 1 (1997) (27)
Induction of specific cytochrome P-450 isozymes by methylenedioxyphenyl compounds and antagonism by 3-methylcholanthrene. (1985) (27)
Comparison of CYP3A4 and CYP3A5: the effects of cytochrome b5 and NADPH-cytochrome P450 reductase on testosterone hydroxylation activities. (2012) (25)
Identification of residues 99, 220, and 221 of human cytochrome P450 2C19 as key determinants of omeprazole activity. (1996) (25)
Epigenetic Modification of Histone 3 Lysine 27 (2014) (25)
The discovery of new coding alleles of human CYP26A1 that are potentially defective in the metabolism of all-trans retinoic acid and their assessment in a recombinant cDNA expression system (2007) (25)
Characterization of a cDNA for rat P-450g, a highly polymorphic, male-specific cytochrome in the P-450IIC subfamily. (1989) (25)
Erectile function and naltrexone. (1986) (23)
Mechanism of induction of hepatic drug metabolizing enzymes: recent advances (1984) (22)
Reversal of in vitro hepatic insulin resistance in chronic pancreatitis by pancreatic polypeptide in the rat. (1989) (22)
Genetic polymorphisms in human drug metabolic enzymes. (1997) (21)
A reciprocal relationship between the induction of -aminolevulinic acid synthetase and drug metabolism produced by m-dichlorobenzene. (1971) (20)
CYP2C9 Genetic Polymorphisms and Warfarin (2004) (18)
CYP2C8 Is a Novel Target of Peroxisome Proliferator-Activated Receptor α in Human Liver (2016) (18)
Involvement of cytochrome P-450c in alpha-naphthoflavone metabolism by rat liver microsomes. (1990) (18)
Cimetidine, ranitidine, and Epstein-Barr virus infection. (1986) (17)
Differential metabolism of acetanilide versus ethoxycoumarin and benzo[a]pyrene by two 3-methylcholanthrene-inducible forms of rat liver cytochrome P-450. (1983) (16)
Activator Protein-1 Regulation of Murine Aldehyde Dehydrogenase 1a1 (2012) (15)
A New CYP3A5 Variant, CYP3A5*11, Is Shown to Be Defective in Nifedipine Metabolism in a Recombinant cDNA Expression System (2007) (15)
The Nuclear Receptors Constitutive Active/Androstane Receptor and Pregnane X Receptor Activate the Cyp2c55 Gene in Mouse Liver (2010) (14)
Detection of Human CYP 2 C 8 , CYP 2 C 9 , and CYP 2 J 2 in Cardiovascular Tissues (2006) (14)
Metabolism of 2-acetylaminofluorene by two 3-methylcholanthrene-inducible forms of rat liver cytochrome P-450. (1984) (14)
Dose response for induction of two cytochrome P-450 isozymes and their mRNAs by 3,4,5,3'4'5'-hexachlorobiphenyl indicating coordinate regulation in rat liver. (1985) (14)
Induction of cytochrome P-450c in hematopoietic cells of fetal liver. (1986) (13)
Induction of rat cytochrome P-450 3 and its mRNA by 3,4,5,3',4',5'-hexachlorobiphenyl. (1987) (12)
Effect of o-benzyl-p-chlorophenol on drug-metabolizing enzymes in rats. (1986) (12)
Associations of ABCB1 and IL-10 Genetic Polymorphisms With Sirolimus-Induced Dyslipidemia in Renal Transplant Recipients (2012) (11)
The influence of the CYP2C19*10 allele on clopidogrel activation and CYP2C19*2 genotyping (2014) (11)
Regulation of Human CYP2C9 Expression by Electrophilic Stress Involves Activator Protein 1 Activation and DNA Looping (2014) (10)
Reduced Methylprednisolone Clearance Causing Prolonged Pharmacodynamics in a Healthy Subject Was Not Associated With CYP3A5*3 Allele or a Change in Diet Composition (2006) (10)
The effects of TCDD on receptors for epidermal growth factor, glucocorticoid, and estrogen in Ah-responsive and -nonresponsive congenic mice and the effects of TCDD on estradiol metabolism in a liver tumor promotion model in female rats. (1990) (9)
NCOA6 differentially regulates the expression of the CYP2C9 and CYP3A4 genes. (2011) (9)
Marked differences in the inductive effects of two symmetrical hexachlorobiphenyls and the corresponding unsymmetrical isomer on hepatic monooxygenases. (1981) (8)
Identification of New Human CYP 2 C 19 Alleles ( CYP 2 C 19 * 6 and CYP 2 C 19 * 2 B ) in a Caucasian Poor Metabolizer of Mephenytoin 1 (1998) (8)
Suppression of male-specific cytochrome P450 2c and its mRNA by 3,4,5,3',4',5'-hexachlorobiphenyl in rat liver is not causally related to changes in serum testosterone. (1989) (8)
Characterization of a cDNA for the unexpressed form of cytochrome P-450g from the (-g) rat and differentiation of its mRNA from that of the (+g) phenotype using specific oligoprobes. (1990) (8)
Effects of dose and route of exposure on dioxin disposition (1992) (7)
CYP2C9 polymorphisms and CYP2C9*2 genotyping primers. (2002) (7)
Med25 is required for estrogen receptor alpha (ERα)-mediated regulation of human CYP2C9 expression. (2014) (6)
Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on hepatic and renal prostaglandin synthetase. (1981) (6)
A Single Amino Acid Mutation ( SerlS 0-- ? ) Cys ) Determines the Polymorphism in Cytochrome P 450 g ( P 4502 C 13 ) by Altering Protein Stability * (2001) (5)
Multiple forms of solubilized and partially resolved cytochrome P-450 from rats induced by 2,3,5,2',3',5'- and 3,4,5,3',4',5'-hexachlorobiphenyls. (1981) (5)
Faculty Opinions recommendation of Pregnane X receptor (PXR) activation: a mechanism for neuroprotection in a mouse model of Niemann-Pick C disease. (2006) (4)
Cimetidine and mononucleosis. (1983) (4)
Structure-activity relationships of chlorinated benzenes as inducers of hepatic cytochrome P-450 isozymes in the rat. (1986) (4)
Effects of 2,3,7,8-tetrachlorodibenzo-dioxin (TCDD) on estradiol metabolism and enzyme-altered foci in a two stage hepatocarcinogenesis model in rats (1989) (3)
Humans exposed to polychlorinated biphenyls (PCBs) and polychlorinated dibenzofurans (PCDFs) exhibit increased SCE frequencies in lymphocytes when incubated with α-naphthoflavone: Involvement of metabolic activation by P-450 isozymes (1989) (3)
Identification of Human CYP2C8 as a Retinoic Acid Receptor-Related Orphan Receptor (ROR) Target Gene 1 (2009) (2)
Polymerization of 4‐vinylpyridine with acylating agents (1972) (2)
Effect of hexachlorobenzene on the specific binding of 2,3,7,8,-TCDD to the hepatic receptor (1986) (2)
CYP 2 C 8 Is a Novel Target of Peroxisome Proliferator-Activated Receptor a in Human Liver s (2015) (1)
The retinoic acid receptor‐related orphan receptor (ROR) regulates human CYP2C8 (1)
PGC‐1α regulates both the constitutive and drug‐inducible expression of human CYP2C9 (2006) (1)
The Nuclear Receptors CAR and PXR Activate the Cyp 2 c 55 Gene in Mouse Liver (2010) (1)
Microsoft Word-91204411-file00 (2010) (0)
DMD048728 398..405 (2013) (0)
Faculty Opinions recommendation of Effects of CYP2C9*1/*13 on the pharmacokinetics and pharmacodynamics of meloxicam. (2011) (0)
Stephen Metabolism in Human Liver Regulating Xenobiotic and Lipid Recruitment to Specific Promoters , Thus Med 25 Is Required for RNA Polymerase II (2011) (0)
Identification and functional studies of human CYP26A1 Single Nucleotide Polymorphisms (SNPs) in racially diverse populations (2006) (0)
PKC phosphorylation of Med25 is critical for Mediator assembly: Implications for HNF4α signaling in drug metabolism (2013) (0)
Faculty Opinions recommendation of Post-transcriptional regulation of human pregnane X receptor by micro-RNA affects the expression of cytochrome P450 3A4. (2008) (0)
Faculty Opinions recommendation of Relative impact of genotype and enzyme induction on the metabolic capacity of CYP2C9 in healthy volunteers. (2010) (0)
Cloning, expression and characterization of three new murine CYP2Cs involved in fatty acid metabolism (2003) (0)
The constitutive androstane receptor mediates phenytoin induction of cyp2c37 (2006) (0)
Cloning and expression of complementary DNAs for multiple members of the human cytochrome PH50IIC subfamily. (1993) (0)
metabolism in a recombinant cDNA expression system (2006) (0)
Ubiquitin Ligase , Interacts with and Ubiquinates the Human Pregnane X Receptor ( hPXR ) (2012) (0)
Epigenetic Modification of Histone 3 Lysine 27 MEDIATORSUBUNITMED25ISREQUIREDFORTHEDISSOCIATIONOFPOLYCOMB REPRESSIVECOMPLEX2FROMTHEPROMOTEROFCYTOCHROMEP4502C9 (2015) (0)
Interethnic Differences in Drug Metabolism and Pharmacogenetics (1995) (0)
Repression of cytochrome P-450 2c and its mRNA by 3,4,5,3',4',5'-hexachlorobiphenyl (HCB), 3-methylcholanthrene (3-MC) and phenobarbital (PB) in livers from male rats (1986) (0)
Genetic Polymorphisms in Human Drug Metabolic Enzymes 1 (2005) (0)
Studies on the Role of the Ah Receptor in Hexachlorobenzene‐Induced Porphyria (1987) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Joyce A. Goldstein?

Joyce A. Goldstein is affiliated with the following schools:

University of Alabama at Birmingham